Literature DB >> 25155591

The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Dhritiman Samanta1, Mohamed O Elasri2.   

Abstract

Vancomycin-intermediate Staphylococcus aureus (VISA) strains present an increasingly difficult problem in terms of public health. However, the molecular mechanism for this resistance is not yet understood. In this study, we define the role of the msaABCR operon in vancomycin resistance in three clinical VISA strains, i.e., Mu50, HIP6297, and LIM2. Deletion of the msaABCR operon resulted in significant decreases in the vancomycin MIC (from 6.25 to 1.56 μg/ml) and significant reductions of cell wall thickness in strains Mu50 and HIP6297. Growth of the mutants in medium containing vancomycin at concentrations greater than 2 μg/ml resulted in decreases in the growth rate, compared with the wild-type strains. Mutation of the msaABCR operon also reduced the binding capacity for vancomycin. We conclude that the msaABCR operon contributes to resistance to vancomycin and cell wall synthesis in S. aureus.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25155591      PMCID: PMC4249426          DOI: 10.1128/AAC.03280-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  73 in total

1.  Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus.

Authors:  J R Aeschlimann; E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Identification and characterization of msa (SA1233), a gene involved in expression of SarA and several virulence factors in Staphylococcus aureus.

Authors:  Karthik Sambanthamoorthy; Mark S Smeltzer; Mohamed O Elasri
Journal:  Microbiology       Date:  2006-09       Impact factor: 2.777

Review 4.  Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.

Authors:  G L French
Journal:  J Antimicrob Chemother       Date:  2006-10-13       Impact factor: 5.790

5.  Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus.

Authors:  K Sieradzki; M G Pinho; A Tomasz
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

6.  Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin.

Authors:  Fionnuala McAleese; Shang Wei Wu; Krzysztof Sieradzki; Paul Dunman; Ellen Murphy; Steven Projan; Alexander Tomasz
Journal:  J Bacteriol       Date:  2006-02       Impact factor: 3.490

Review 7.  Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

8.  Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Xiaoxue Ma; Katsuhiro Sato; Keiko Okuma; Fred C Tenover; Elsa M Mamizuka; Curtis G Gemmell; Mi-Na Kim; Marie-Cecile Ploy; N El-Solh; Vivian Ferraz; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

9.  Impact of sigB mutation on Staphylococcus aureus oxacillin and vancomycin resistance varies with parental background and method of assessment.

Authors:  Vineet K Singh; Jennifer L Schmidt; R K Jayaswal; Brian J Wilkinson
Journal:  Int J Antimicrob Agents       Date:  2003-03       Impact factor: 5.283

10.  Dispersed mode of Staphylococcus aureus cell wall synthesis in the absence of the division machinery.

Authors:  Mariana G Pinho; Jeff Errington
Journal:  Mol Microbiol       Date:  2003-11       Impact factor: 3.501

View more
  8 in total

1.  MsaB activates capsule production at the transcription level in Staphylococcus aureus.

Authors:  Justin L Batte; Dhritiman Samanta; Mohamed O Elasri
Journal:  Microbiology       Date:  2016-01-18       Impact factor: 2.777

2.  The msaABCR Operon Regulates the Response to Oxidative Stress in Staphylococcus aureus.

Authors:  Shanti Pandey; Gyan S Sahukhal; Mohamed O Elasri
Journal:  J Bacteriol       Date:  2019-10-04       Impact factor: 3.490

3.  MsaB and CodY Interact To Regulate Staphylococcus aureus Capsule in a Nutrient-Dependent Manner.

Authors:  Justin L Batte; Gyan S Sahukhal; Mohamed O Elasri
Journal:  J Bacteriol       Date:  2018-08-10       Impact factor: 3.490

4.  Role of the msaABCR Operon in Cell Wall Biosynthesis, Autolysis, Integrity, and Antibiotic Resistance in Staphylococcus aureus.

Authors:  Bibek G C; Gyan S Sahukhal; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

5.  Delineating the Role of the msaABCR Operon in Staphylococcal Overflow Metabolism.

Authors:  Bibek G C; Gyan S Sahukhal; Mohamed O Elasri
Journal:  Front Microbiol       Date:  2022-06-03       Impact factor: 6.064

Review 6.  Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus.

Authors:  Qiwen Hu; Huagang Peng; Xiancai Rao
Journal:  Front Microbiol       Date:  2016-10-13       Impact factor: 5.640

7.  msaABCR operon is involved in persister cell formation in Staphylococcus aureus.

Authors:  Gyan S Sahukhal; Shanti Pandey; Mohamed O Elasri
Journal:  BMC Microbiol       Date:  2017-11-22       Impact factor: 3.605

8.  Molecular Characterization of Vancomycin, Mupirocin and Antiseptic Resistant Staphylococcus aureus Strains.

Authors:  Mahtab Hadadi; Hamid Heidari; Hadi Sedigh Ebrahim-Saraie; Mohammad Motamedifar
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.